Roee Shahar
About Roee Shahar
Executive Vice President, Commercial at Immunome (IMNM), appointed October 8, 2024, with 20+ years in oncology/hematology commercialization at Pfizer (post-Seagen acquisition), Seagen, and Eli Lilly. He led franchises for ADCETRIS (hematology) and TIVDAK (cervical cancer) at Seagen and subsequently managed Pfizer’s combined hematology portfolio; he holds a B.S. from Indiana University’s Kelley School of Business . Immunome’s policies prohibit hedging, margin purchases, and pledging of company stock, supporting alignment with shareholders . Company performance context is below.
Company Performance (for context)
Values retrieved from S&P Global.
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Revenues (USD) | $14,018,000 * | $9,041,000 * |
| EBITDA (USD) | -$28,271,000* | -$151,889,000* |
*Values retrieved from S&P Global
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Pfizer | Vice President & Franchise Lead, hematology portfolio post-Seagen acquisition | Not disclosed | Managed combined hematology portfolio integration and commercialization post-Seagen acquisition . |
| Seagen | Vice President & Franchise Lead, hematology (ADCETRIS) and cervical cancer (TIVDAK) | Not disclosed | Led franchise strategy and launches for ADCETRIS and TIVDAK; foundations in targeted oncology commercialization . |
| Eli Lilly & Company | Marketing Director & Oncology Brand Leader (Alimta) | Not disclosed | Led marketing for Lilly’s largest oncology brand at the time, Alimta, enhancing oncology market execution . |
External Roles
| Category | Disclosed Details |
|---|---|
| Public company directorships | None disclosed for Shahar in Immunome’s filings; listed as management team member (EVP, Commercial) . |
Equity Ownership & Alignment
- Insider Trading Policy: Directors, officers, employees and certain consultants are prohibited from hedging, purchasing on margin, borrowing against company stock, or pledging Immunome shares as collateral .
- Clawback: All awards are subject to recoupment under exchange listing standards and Dodd-Frank; Board may impose additional clawback provisions .
- Inducement Plan mechanics (context for new hires): Options carry 10-year terms, strike price ≥ FMV, typical vesting 25% at 1-year anniversary then monthly over 36 months; RSUs/other awards permitted; no repricing without shareholder approval .
- Note: Shahar’s individual equity holdings and grants are not disclosed in the proxy or 8-Ks; Inducement grant press releases aggregate new-hire options without naming specific individuals .
Employment Terms
- Appointment: Announced by Immunome on October 8, 2024 as EVP, Commercial .
- Contract economics: Not disclosed in SEC filings reviewed (no Item 5.02 8-K naming Shahar).
- Company-wide award treatment (context): Options/RSUs feature standard post-termination exercise windows; change-in-control treatment outlined at plan level (assumption/substitution/acceleration subject to Board determination and Section 409A compliance) .
Compensation Committee Analysis (company context)
- Committee members: James Boylan (Chair), Isaac Barchas, Jean‑Jacques Bienaimé; all independent .
- Consultant: Radford/Aon engaged since 2021; approach targets ~50th percentile for cash and ~75th percentile for equity versus peers, subject to discretion based on experience/performance .
- Clawback oversight: Compensation Committee approves and oversees application of clawbacks .
Performance & Track Record
- Execution credentials: Shahar led commercialization for ADCETRIS and TIVDAK at Seagen and later managed Pfizer’s combined hematology portfolio post-Seagen acquisition, signaling strong launch and lifecycle management expertise in targeted oncology .
- Role in Immunome’s pipeline commercial readiness: Leadership cited by CEO in public remarks as a strength ahead of AL102 (varegacestat) Phase 3 topline data expected in 2025, and broader portfolio (ADCs, RLT) .
- Management team listing: Immunome’s 10-K includes Shahar as EVP, Commercial among the executive leadership team .
Say‑on‑Pay & Shareholder Feedback (company context)
- Status transition: As of June 30, 2025, IMNM exceeded $700M public float; it will cease to be an emerging growth company effective December 31, 2025 and a smaller reporting company beginning Q1 2026, triggering more detailed executive compensation disclosures and non-binding say‑on‑pay votes thereafter .
Investment Implications
- Alignment and risk: Hedging and pledging prohibitions materially reduce misalignment/forced selling risk; clawback coverage strengthens governance signals .
- Execution lever: Shahar’s prior franchise leadership across ADCETRIS/TIVDAK and Pfizer hematology should enhance Immunome’s launch preparedness for AL102 and future targeted oncology assets, mitigating commercial execution risk .
- Information gaps: Lack of disclosed individual compensation, grant sizes, vesting specifics, and ownership for Shahar limit pay‑for‑performance assessment, monitoring for insider selling pressure, and equity alignment analysis (NEO disclosures do not include Shahar) .
- Upcoming disclosure cadence: Expanded compensation and say‑on‑pay disclosures expected as IMNM transitions out of emerging growth/smaller reporting status, improving visibility into executive incentives and retention risk in 2026+ .